Reasons for discontinuation
| Reason for discontinuation . | n . |
|---|---|
| Infection | 7 |
| Progression | 4 |
| Patient preference∗ | 4 |
| Cough | 4 |
| Financial† | 3 |
| Second primary cancer‡ | 1 |
| Transformation | 1 |
| Arthritis | 1 |
| Investigator discretion | 1 |
| Sick sinus syndrome | 1 |
| Ineligible§ | 1 |
| Abdominal pain | 1 |
| Fatigue | 1 |
| Neutropenia | 1 |
| Poor wound healing | 1 |
| Reason for discontinuation . | n . |
|---|---|
| Infection | 7 |
| Progression | 4 |
| Patient preference∗ | 4 |
| Cough | 4 |
| Financial† | 3 |
| Second primary cancer‡ | 1 |
| Transformation | 1 |
| Arthritis | 1 |
| Investigator discretion | 1 |
| Sick sinus syndrome | 1 |
| Ineligible§ | 1 |
| Abdominal pain | 1 |
| Fatigue | 1 |
| Neutropenia | 1 |
| Poor wound healing | 1 |
Two patients had upper airway cough syndrome, 2 patients had concerns because of risk associated with COVID-19 pandemic.
One patient had a change in insurance and 2 patients lost insurance.
Noninvasive bladder cancer.
Patient with biopsy-proven transformation after having received 1 dose of study drug combination.